Unique ID issued by UMIN | UMIN000013114 |
---|---|
Receipt number | R000015277 |
Scientific Title | Prospective study for prevention of insufficiency fracture after pelvic irradiation with alendronate and vitamin D |
Date of disclosure of the study information | 2014/02/19 |
Last modified on | 2015/02/22 17:18:37 |
Prospective study for prevention of insufficiency fracture after pelvic irradiation with alendronate and vitamin D
Prospective study for prevention of insufficiency fracture with alendronate and vitamin D
Prospective study for prevention of insufficiency fracture after pelvic irradiation with alendronate and vitamin D
Prospective study for prevention of insufficiency fracture with alendronate and vitamin D
Japan |
Uterine cervical cancer
Radiology |
Malignancy
NO
To evaluate the effectiveness of alendronate and vitamin D to prevent insufficiency fracture after definitive radiation therapy for cervical cancer.
Safety,Efficacy
Exploratory
The incidence of insufficiency fracture after definitive radiation therapy in patients with cervical cancer who are prescribed with alendronate and vitamin D.
1.The incidence of symptomatic insufficiency fracture after definitive radiation therapy (RT) in patients with cervical cancer who are prescribed with alendronate and vitamin D. 2.The change of bone density after the RT. 3.The change of bone metabolism markers after the RT. 4.The adverese effect of alendronate and vitamin D.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Prevention
Medicine |
Introduce alendronate and vitamin D at the initiation of radiation therapy for cervical cancer.
45 | years-old | <= |
Not applicable |
Female
1)Female whose age is 45 year or more or postmenopause
2)Diagnosed with osteoporosis
3)Candidate for definitive radiation therapy for cervical cancer
4)ECOG Performance status < 2
1)Patients with esophageal disorder
2)Patients who cannot sit upright for 30 minuites
3)Patients with a history of allergy to bisphosphonate or vitamin D
4)Patients with hypocalcemia who need treatment
5)Patients with severely impaired renal function (serum creatinine >1.5mg/dL)
6)Patients with severely impaired liver or heart function
7)Patients who were treated with antiosteoporotic medication
8)Patients who are planned to undergo intensity modulated radiation therapy
9)Patients who are considered to be inappropriate by the physician
27
1st name | |
Middle name | |
Last name | Miyawaki Daisuke |
Kobe University Hospital
Radiation Oncology
7-5-1 Kusunoki-Chou, Chuou-Ku, Kobe, Hyogo
078-382-6104
miyawaki@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Miyawaki Daisuke |
Kobe University Hospital
Radiation Oncology
7-5-1 Kusunoki-Chou, Chuou-Ku, Kobe, Hyogo
078-382-6104
miyawaki@med.kobe-u.ac.jp
Kobe University Graduate School of Medicine, Division of Radiation Oncology
Kobe University Graduate School of Medicine, Division of Radiation Oncology
Self funding
Japan
NO
2014 | Year | 02 | Month | 19 | Day |
Unpublished
Preinitiation
2014 | Year | 01 | Month | 20 | Day |
2014 | Year | 03 | Month | 01 | Day |
2017 | Year | 08 | Month | 31 | Day |
2014 | Year | 02 | Month | 09 | Day |
2015 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015277
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |